EyePoint, Inc. (formerly EyePoint Pharmaceuticals) Overview
Pro stress-test →EyePoint, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company developing innovative sustained intraocular drug delivery therapies for serious retinal diseases. The company focuses on wet AMD, diabetic macular edema, and non-proliferative diabetic retinopathy using its proprietary Durasert E bioerodible platform technology, which has safely been administered to thousands of patients across four FDA-approved products.
Strategic Profile
Pro stress-test →EyePoint is strategically positioned as a pure-play retinal disease specialist, leveraging three decades of validated drug delivery experience. The company has transitioned from a diversified pharma portfolio to a focused clinical-stage competitor by exiting its specialty pharma business, allowing concentrated resources for DURAVYU, its lead investigational product combining a patent-protected tyrosine kinase inhibitor with Durasert E technology.
Competitive Landscape
Pro stress-test →EyePoint competes in the wet AMD and diabetic retinal disease treatment market against established antiVEGF therapies (Avastin, Eylea, Beovu) and emerging sustained-delivery competitors. Key differentiation lies in Durasert E's claimed durability and patient convenience advantages, positioning DURAVYU as a next-generation option if clinical efficacy validates superiority. The retinal disease market is consolidating with biosimilars and new mechanisms of action intensifying competition.
Industry Context
EyePoint, Inc. (formerly EyePoint Pharmaceuticals) operates in Biopharmaceuticals/Ophthalmology - Retinal Disease Therapeutics.
Key facts
Founded: 1987 · Headquarters: Watertown, Massachusetts, US · Employees: 165 · Revenue: $43.3M (2024) · Market cap: $1.2B